Cargando…

Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp

BACKGROUND: Aminolevulinic acid photodynamic therapy (ALA-PDT) can be effective and well tolerated when applied over a broad area and for short drug incubation times. OBJECTIVE: To evaluate the effect of short-incubation time and application method on the safety and efficacy of ALA-PDT versus vehicl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pariser, David M., Houlihan, Anna, Ferdon, Mary Beth, Berg, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414777/
https://www.ncbi.nlm.nih.gov/pubmed/26863596
http://dx.doi.org/10.1097/DSS.0000000000000630
_version_ 1783233416738635776
author Pariser, David M.
Houlihan, Anna
Ferdon, Mary Beth
Berg, James E.
author_facet Pariser, David M.
Houlihan, Anna
Ferdon, Mary Beth
Berg, James E.
author_sort Pariser, David M.
collection PubMed
description BACKGROUND: Aminolevulinic acid photodynamic therapy (ALA-PDT) can be effective and well tolerated when applied over a broad area and for short drug incubation times. OBJECTIVE: To evaluate the effect of short-incubation time and application method on the safety and efficacy of ALA-PDT versus vehicle (VEH-PDT) in the treatment of actinic keratoses (AKs) of the face or scalp. METHODS: Aminolevulinic acid or VEH was applied to face or scalp as a broad area application for 1, 2, or 3 hours or as a spot application for 2 hours before blue light activation. An identical treatment was repeated at Week 8 if any AK lesions remained. RESULTS: Median AK clearance rate for ALA-treated subjects ranged from 68% to 79% at Week 12, compared with 7% of the VEH-treated group (p < .0001). Complete clearance rate for ALA-treated subjects ranged from 17% (8/46) to 30% (14/47) at Week 12, compared with 2% (1/46) of the VEH-treated group (p = .0041). The safety profile seen in this study is consistent with previously reported side effects of the therapy. CONCLUSION: Short-incubation ALA-PDT was found to be superior to VEH-PDT for AK lesion clearance. A second treatment improves efficacy.
format Online
Article
Text
id pubmed-5414777
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-54147772017-05-10 Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp Pariser, David M. Houlihan, Anna Ferdon, Mary Beth Berg, James E. Dermatol Surg Original Article BACKGROUND: Aminolevulinic acid photodynamic therapy (ALA-PDT) can be effective and well tolerated when applied over a broad area and for short drug incubation times. OBJECTIVE: To evaluate the effect of short-incubation time and application method on the safety and efficacy of ALA-PDT versus vehicle (VEH-PDT) in the treatment of actinic keratoses (AKs) of the face or scalp. METHODS: Aminolevulinic acid or VEH was applied to face or scalp as a broad area application for 1, 2, or 3 hours or as a spot application for 2 hours before blue light activation. An identical treatment was repeated at Week 8 if any AK lesions remained. RESULTS: Median AK clearance rate for ALA-treated subjects ranged from 68% to 79% at Week 12, compared with 7% of the VEH-treated group (p < .0001). Complete clearance rate for ALA-treated subjects ranged from 17% (8/46) to 30% (14/47) at Week 12, compared with 2% (1/46) of the VEH-treated group (p = .0041). The safety profile seen in this study is consistent with previously reported side effects of the therapy. CONCLUSION: Short-incubation ALA-PDT was found to be superior to VEH-PDT for AK lesion clearance. A second treatment improves efficacy. Lippincott Williams & Wilkins 2016-03 2016-03-14 /pmc/articles/PMC5414777/ /pubmed/26863596 http://dx.doi.org/10.1097/DSS.0000000000000630 Text en © 2016 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Article
Pariser, David M.
Houlihan, Anna
Ferdon, Mary Beth
Berg, James E.
Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
title Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
title_full Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
title_fullStr Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
title_full_unstemmed Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
title_short Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
title_sort randomized vehicle-controlled study of short drug incubation aminolevulinic acid photodynamic therapy for actinic keratoses of the face or scalp
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414777/
https://www.ncbi.nlm.nih.gov/pubmed/26863596
http://dx.doi.org/10.1097/DSS.0000000000000630
work_keys_str_mv AT pariserdavidm randomizedvehiclecontrolledstudyofshortdrugincubationaminolevulinicacidphotodynamictherapyforactinickeratosesofthefaceorscalp
AT houlihananna randomizedvehiclecontrolledstudyofshortdrugincubationaminolevulinicacidphotodynamictherapyforactinickeratosesofthefaceorscalp
AT ferdonmarybeth randomizedvehiclecontrolledstudyofshortdrugincubationaminolevulinicacidphotodynamictherapyforactinickeratosesofthefaceorscalp
AT bergjamese randomizedvehiclecontrolledstudyofshortdrugincubationaminolevulinicacidphotodynamictherapyforactinickeratosesofthefaceorscalp
AT randomizedvehiclecontrolledstudyofshortdrugincubationaminolevulinicacidphotodynamictherapyforactinickeratosesofthefaceorscalp